Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma
Exploration of Targeted Anti-tumor Therapy · 20.09.2024 · 5 (6) · 1199-1222
DOI: 10.37349/etat.2024.00271 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 20.09.2024. Verfasst von Loubna Omri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Institute of Oncology, Rabat X4FH+66, Morocco. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant improvements in survival and the achievement of sustained long-term responses, a subset of patients remains refractory to ICI, and most will eventually develop resistance. Thus, identifying predictive biomarkers for ICI efficacy and resistance is essential for optimizing therapeutic strategies. Up to now, tissue-based biomarkers have not been successful as predictive biomarkers in RCC. Circulating blood-based biomarkers offer a promising alternative. These biomarkers, including circulating immune cells, soluble factors, tumor-derived markers, and those based on metabolomics, are less invasive, offer reproducibility over time, and provide a comprehensive assessment of tumor biology and patient immune status, as well as allow dynamic monitoring during treatment. This review aims to evaluate the current evidence on the different candidate circulating biomarkers being investigated for their potential to predict ICI efficacy in RCC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, National Institute of Oncology, Rabat X4FH+66, Morocco.
- Medical Oncology Department, Centre Hospitalier Universitaire Brugmann, 1020 Brussels, Belgium.
- Laboratory of Immunomonitoring in Oncology, Gustave Roussy, 94805 Villejuif, France.
- Paris-Saclay University, School of Pharmacy, 91190 Orsay, France.
- Medical Oncology Department, Institut Gustave Roussy, 94805 Villejuif, France.
- Medical Oncology Department, Centre Hospitalier Universitaire Saint-Pierre, 1000 Brussels, Belgium.
Zitieren
APA
Omri, L., Naigeon, M., Flippot, R., Gavira-Díaz, J., Poveda-Ferriols, J., Nguyen, D., Abdi, C., Arroyo-Salgado, A., Chaput, N., de Velasco, G., Albigès, L., & Carril-Ajuria, L. (2024). Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma. Exploration of Targeted Anti-tumor Therapy, 5(6), 1199-1222. https://doi.org/10.37349/etat.2024.00271
Vancouver
Omri L, Naigeon M, Flippot R, Gavira-Díaz J, Poveda-Ferriols J, Nguyen D, et al. Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma. Exploration of Targeted Anti-tumor Therapy. 2024;5(6):1199-1222. doi:10.37349/etat.2024.00271
BibTeX
@article{Omri2024,
author = {Omri, Loubna and Naigeon, Marie and Flippot, Ronan and Gavira-Díaz, Javier and Poveda-Ferriols, Jesus and Nguyen, Dan and Abdi, Chaimae and Arroyo-Salgado, Alvaro and Chaput, Nathalie and de Velasco, Guillermo and Albigès, Laurence and Carril-Ajuria, Lucía},
title = {Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma},
journal = {Exploration of Targeted Anti-tumor Therapy},
year = {2024},
volume = {5},
number = {6},
pages = {1199--1222},
doi = {10.37349/etat.2024.00271}
}
EUVIMED